Proteomics as a tool to discover biomarkers for the prediction of diabetic complications

Bibliography

• Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-97
   PubMed Web of Science ®Google Scholar
• Kahn SE, Montgomery B, Howell W, et al. Importance of early Phase Insulin secretion to intravenous glucose tolerance in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 2001;86:5824-9
   PubMed Web of Science ®Google Scholar
• Porte D Jr, Kahn SE. Beta-cell dysfunction and failure in type 2 diabetes: potential mechanisms. Diabetes 2001;50 Suppl 1:S160-3
   PubMed Web of Science ®Google Scholar
• Butler AE, Janson J, Bonner-Weir S, et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003;52:102-10
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation homepage Available from: URL: www.idf.org [last accessed February 2008]
   Google Scholar
• Higgins GT, Khan J, Pearce IA. Glycaemic control and control of risk factors in diabetes patients in an ophthalmology clinic: what lessons have we learned from the UKPDS and DCCT studies? Acta Ophthalmol Scand 2007;85:772-6
   PubMedGoogle Scholar
• The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 1995;44:968-83
   PubMed Web of Science ®Google Scholar
• Krentz AJ. UKPDS and beyond: into the next millennium. United Kingdom Prospective Diabetes Study. Diabetes Obes Metab 1999;1:13-22
   PubMed Web of Science ®Google Scholar
• Manley S. Haemoglobin A1c-a marker for complications of type 2 diabetes: the experience from the UK Prospective Diabetes Study (UKPDS). Clin Chem Lab Med 2003;41:1182-90
   PubMed Web of Science ®Google Scholar
• Sundsten T, Eberhardson M, Goransson M, Bergsten P. The use of proteomics in identifying differentially expressed serum proteins in humans with type 2 diabetes. Proteome Sci 2006;4:22
   PubMedGoogle Scholar
• Varughese GI, Lip GY. Is hypertension a prothrombotic state? Curr Hypertens Rep 2005;7:168-73
   PubMed Web of Science ®Google Scholar
• Boyle PJ. Diabetes mellitus and macrovascular disease: mechanisms and mediators. Am J Med 2007;120:S12-7
   PubMed Web of Science ®Google Scholar
• Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000;342:1792-801
   PubMed Web of Science ®Google Scholar
• Kelkar P. Diabetic neuropathy. Semin Neurol 2005;25:168-73
   PubMed Web of Science ®Google Scholar
• Wolf G, Ritz E. Diabetic nephropathy in type 2 diabetes prevention and patient management. J Am Soc Nephrol 2003;14:1396-405
   PubMed Web of Science ®Google Scholar
• Viberti GC, Jarrett RJ, Keen H. Microalbuminuria as prediction of nephropathy in diabetics. Lancet 1982;2:611
   PubMedGoogle Scholar
• Remuzzi G, Schieppati A, Ruggenenti P. Clinical practice. Nephropathy in patients with type 2 diabetes. N Engl J Med 2002;346:1145-51
   PubMed Web of Science ®Google Scholar
• Ng DP, Krolewski AS. Molecular genetic approaches for studying the etiology of diabetic nephropathy. Curr Mol Med 2005;5:509-25
   PubMed Web of Science ®Google Scholar
• Jones CA, Krolewski AS, Rogus J, et al. Epidemic of end-stage renal disease in people with diabetes in the United States population: do we know the cause? Kidney Int 2005;67:1684-91
   PubMed Web of Science ®Google Scholar
• Parving HH. Diabetic nephropathy: prevention and treatment. Kidney Int 2001;60:2041-55
   PubMed Web of Science ®Google Scholar
• Mykkanen L, Haffner SM, Kuusisto J, et al. Microalbuminuria precedes the development of NIDDM. Diabetes 1994;43:552-7
   PubMed Web of Science ®Google Scholar
• Bennett PH, Haffner S, Kasiske BL, et al. Screening and management of microalbuminuria in patients with diabetes mellitus: recommendations to the Scientific Advisory Board of the National Kidney Foundation from an ad hoc committee of the Council on Diabetes Mellitus of the National Kidney Foundation. Am J Kidney Dis 1995;25:107-12
   PubMed Web of Science ®Google Scholar
• Molitch ME. How long should insulin be used once a vial is started? Diabetes Care 2004;27:1240-1
   PubMedGoogle Scholar
• Caramori ML, Mauer M. Diabetes and nephropathy. Curr Opin Nephrol Hypertens 2003;12:273-82
   PubMed Web of Science ®Google Scholar
• Congdon NG, Friedman DS, Lietman T. Important causes of visual impairment in the world today. JAMA 2003;290:2057-60
   PubMed Web of Science ®Google Scholar
• Lovestam-Adrian M, Agardh CD, Torffvit O, Agardh E. Diabetic retinopathy, visual acuity, and medical risk indicators: a continuous 10-year follow-up study in Type 1 diabetic patients under routine care. J Diabetes Complications 2001;15:287-94
   PubMed Web of Science ®Google Scholar
• Voutilainen-Kaunisto RM, Terasvirta ME, Uusitupa MI, Niskanen LK. Occurrence and predictors of retinopathy and visual acuity in Type 2 diabetic patients and control subjects. 10-year follow-up from the diagnosis. J Diabetes Complications 2001;15:24-33
   PubMed Web of Science ®Google Scholar
• Wilkins MR, Sanchez JC, Gooley AA, et al. Progress with proteome projects: why all proteins expressed by a genome should be identified and how to do it. Biotechnol Genet Eng Rev 1996;13:19-50
   PubMed Web of Science ®Google Scholar
• O'Farrell PH. High resolution two-dimensional electrophoresis of proteins. J Biol Chem 1975;250:4007-21
   PubMed Web of Science ®Google Scholar
• Alban A, David SO, Bjorkesten L, et al. A novel experimental design for comparative two-dimensional gel analysis: two-dimensional difference gel electrophoresis incorporating a pooled internal standard. Proteomics 2003;3:36-44
   PubMed Web of Science ®Google Scholar
• Knowles MR, Cervino S, Skynner HA, et al. Multiplex proteomic analysis by two-dimensional differential in-gel electrophoresis. Proteomics 2003;3:1162-71
   PubMed Web of Science ®Google Scholar
• Van den BG, Arckens L. Fluorescent two-dimensional difference gel electrophoresis unveils the potential of gel-based proteomics. Curr Opin Biotechnol 2004;15:38-43
   PubMed Web of Science ®Google Scholar
• Herbert B. Advances in protein solubilisation for two-dimensional electrophoresis. Electrophoresis 1999;20:660-3
   PubMed Web of Science ®Google Scholar
• Castellanos-Serra L, Paz-Lago D. Inhibition of unwanted proteolysis during sample preparation: evaluation of its efficiency in challenge experiments. Electrophoresis 2002;23:1745-53
   PubMed Web of Science ®Google Scholar
• Gorg A, Weiss W, Dunn MJ. Current two-dimensional electrophoresis technology for proteomics. Proteomics 2004;4:3665-85
   PubMed Web of Science ®Google Scholar
• Merchant M, Weinberger SR. Recent advancements in surface-enhanced laser desorption/ionization-time of flight-mass spectrometry. Electrophoresis 2000;21:1164-77
   PubMed Web of Science ®Google Scholar
• Issaq HJ, Veenstra TD, Conrads TP, Felschow D. The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. Biochem Biophys Res Commun 2002;292:587-92
   PubMed Web of Science ®Google Scholar
• Poon TC. Opportunities and limitations of SELDI-TOF-MS in biomedical research: practical advices. Expert Rev Proteomics 2007;4:51-65
   PubMed Web of Science ®Google Scholar
• Zhang R, Barker L, Pinchev D, et al. Mining biomarkers in human sera using proteomic tools. Proteomics 2004;4:244-56
   PubMed Web of Science ®Google Scholar
• Tammen H, Schulte I, Hess R, et al. Peptidomic analysis of human blood specimens: comparison between plasma specimens and serum by differential peptide display. Proteomics 2005;5:3414-22
   PubMed Web of Science ®Google Scholar
• Blanco-Colio LM, Martin-Ventura JL, Vivanco F, et al. Biology of atherosclerotic plaques: what we are learning from proteomic analysis. Cardiovasc Res 2006;72:18-29
   PubMed Web of Science ®Google Scholar
• Cho WC, Yip TT, Chung WS, et al. Potential biomarkers found by protein profiling may provide insight for the macrovascular pathogenesis of diabetes mellitus. Dis Markers 2006;22:153-66
   PubMed Web of Science ®Google Scholar
• Ahren B, Gutniak M. No correlation between insulin and islet amyloid polypeptide after stimulation with glucagon-like peptide-1 in type 2 diabetes. Eur J Endocrinol 1997;137:643-9
   PubMed Web of Science ®Google Scholar
• Stridsberg M, Berne C, Sandler S, et al. Inhibition of insulin secretion, but normal peripheral insulin sensitivity, in a patient with a malignant endocrine pancreatic tumour producing high amounts of an islet amyloid polypeptide-like molecule. Diabetologia 1993;36:843-9
   PubMed Web of Science ®Google Scholar
• Schaffler A, Buchler C, Muller-Ladner U, et al. Identification of variables influencing resistin serum levels in patients with type 1 and type 2 diabetes mellitus. Horm Metab Res 2004;36:702-7
   PubMed Web of Science ®Google Scholar
• Davidsson P, Hulthe J, Fagerberg B, et al. A proteomic study of the apolipoproteins in LDL subclasses in patients with the metabolic syndrome and type 2 diabetes. J Lipid Res 2005;46:1999-2006
   PubMed Web of Science ®Google Scholar
• Hurt-Camejo E, Camejo G, Rosengren B, et al. Differential uptake of proteoglycan-selected subfractions of low density lipoprotein by human macrophages. J Lipid Res 1990;31:1387-98
   PubMed Web of Science ®Google Scholar
• Lee SJ, Campos H, Moye LA, Sacks FM. LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients. Arterioscler Thromb Vasc Biol 2003;23:853-8
   PubMed Web of Science ®Google Scholar
• Gervaise N, Garrigue MA, Lasfargues G, Lecomte P. Triglycerides, apo C3 and Lp B:C3 and cardiovascular risk in type II diabetes. Diabetologia 2000;43:703-8
   PubMed Web of Science ®Google Scholar
• Rohrer L, Hersberger M, von EA. High density lipoproteins in the intersection of diabetes mellitus, inflammation and cardiovascular disease. Curr Opin Lipidol 2004;15:269-78
   PubMed Web of Science ®Google Scholar
• Matsumura T, Suzuki T, Kada N, et al. Differential serum proteomic analysis in a model of metabolic disease. Biochem Biophys Res Commun 2006;351:965-71
   PubMed Web of Science ®Google Scholar
• Srinivas PR, Wagner AS, Reddy LV, et al. Serum alpha 2-HS-glycoprotein is an inhibitor of the human insulin receptor at the tyrosine kinase level. Mol Endocrinol 1993;7:1445-55
   PubMed Web of Science ®Google Scholar
• Hu XJ, Peng F, Zhou HQ, et al. The abnormality of glucose transporter in the erythrocyte membrane of Chinese type 2 diabetic patients. Biochim Biophys Acta 2000;1466:306-14
   PubMed Web of Science ®Google Scholar
• Cho WC, Yip TT, Chung WS, et al. Differential expression of proteins in kidney, eye, aorta, and serum of diabetic and non-diabetic rats. J Cell Biochem 2006;99:256-68
   PubMed Web of Science ®Google Scholar
• Chase HP, Cooper S, Osberg I, et al. Elevated C-reactive protein levels in the development of type 1 diabetes. Diabetes 2004;53:2569-73
   PubMed Web of Science ®Google Scholar
• Doi Y, Kiyohara Y, Kubo M, et al. Elevated C-reactive protein is a predictor of the development of diabetes in a general Japanese population: the Hisayama Study. Diabetes Care 2005;28:2497-500
   PubMed Web of Science ®Google Scholar
• Tajiri Y, Mimura K, Umeda F. High-sensitivity C-reactive protein in Japanese patients with type 2 diabetes. Obes Res 2005;13:1810-6
   PubMedGoogle Scholar
• Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448-54
   PubMed Web of Science ®Google Scholar
• Garcia-Ramirez M, Canals F, Hernandez C, et al. Proteomic analysis of human vitreous fluid by fluorescence-based difference gel electrophoresis (DIGE): a new strategy for identifying potential candidates in the pathogenesis of proliferative diabetic retinopathy. Diabetologia 2007;50:1294-303
   PubMed Web of Science ®Google Scholar
• Spranger J, Osterhoff M, Reimann M, et al. Loss of the antiangiogenic pigment epithelium-derived factor in patients with angiogenic eye disease. Diabetes 2001;50:2641-5
   PubMed Web of Science ®Google Scholar
• Ogata N, Tombran-Tink J, Nishikawa M, et al. Pigment epithelium-derived factor in the vitreous is low in diabetic retinopathy and high in rhegmatogenous retinal detachment. Am J Ophthalmol 2001;132:378-82
   PubMed Web of Science ®Google Scholar
• Barnstable CJ, Tombran-Tink J. Neuroprotective and antiangiogenic actions of PEDF in the eye: molecular targets and therapeutic potential. Prog Retin Eye Res 2004;23:561-77
   PubMed Web of Science ®Google Scholar
• Dawson DW, Volpert OV, Gillis P, et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999;285:245-8
   PubMed Web of Science ®Google Scholar
• Gohda T, Makita Y, Shike T, et al. Identification of epistatic interaction involved in obesity using the KK/Ta mouse as a Type 2 diabetes model: is Zn-alpha2 glycoprotein-1 a candidate gene for obesity? Diabetes 2003;52:2175-81
   PubMed Web of Science ®Google Scholar
• Gohda T, Tanimoto M, Shiina K, et al. Altered mouse cholinephosphotransferase gene expression in kidneys of type 2 diabetic KK/TA mouse. Metabolism 2004;53:842-6
   PubMed Web of Science ®Google Scholar
• Rao PV, Lu X, Standley M, et al. Proteomic identification of urinary biomarkers of diabetic nephropathy. Diabetes Care 2007;30:629-37
   PubMed Web of Science ®Google Scholar
• Retnakaran R, Zinman B, Connelly PW, et al. Nontraditional cardiovascular risk factors in pediatric metabolic syndrome. J Pediatr 2006;148:176-82
   PubMed Web of Science ®Google Scholar
• Dihazi H, Muller GA, Lindner S, et al. Characterization of diabetic nephropathy by urinary proteomic analysis: identification of a processed ubiquitin form as a differentially excreted protein in diabetic nephropathy patients. Clin Chem 2007;53:1636-45
   PubMed Web of Science ®Google Scholar
• Schaub S, Wilkins JA, Antonovici M, et al. Proteomic-based identification of cleaved urinary beta2-microglobulin as a potential marker for acute tubular injury in renal allografts. Am J Transplant 2005;5:729-38
   PubMed Web of Science ®Google Scholar
• Hong CY, Chia KS. Markers of diabetic nephropathy. J Diabetes Complications 1998;12:43-60
   PubMed Web of Science ®Google Scholar
• Hershko A, Ciechanover A. The ubiquitin system. Ann Rev Biochem 1998;67:425-79
   PubMed Web of Science ®Google Scholar
• Otu HH, Can H, Spentzos D, et al. Prediction of diabetic nephropathy using urine proteomic profiling 10 years prior to development of nephropathy. Diabetes Care 2007;30:638-43
   PubMed Web of Science ®Google Scholar
• Mischak H, Kaiser T, Walden M, et al. Proteomic analysis for the assessment of diabetic renal damage in humans. Clin Sci (Lond) 2004;107:485-95
   PubMed Web of Science ®Google Scholar
• Torffvit O, Agardh CD, Thulin T. A study of Tamm-Horsfall protein excretion in hypertensive patients and type 1 diabetic patients. Scand J Urol Nephrol 1999;33:187-91
   PubMed Web of Science ®Google Scholar